NAD+ — The Coenzyme at the Centre of Longevity Biology

Not everything in the Longevity section of this library is a peptide. NAD+ — nicotinamide adenine dinucleotide — is a coenzyme rather than a peptide, but its central position in the biology of ageing makes it impossible to cover the longevity landscape honestly without addressing it directly. It appears on this page because it is covered in the sitemap, because it connects to the mechanisms of virtually every other compound in this section, and because the evidence around it — more extensively studied in humans than almost any other longevity intervention — is genuinely worth understanding in full.

The concept is elegant and the biological rationale is compelling. NAD+ is essential for cellular energy metabolism, DNA repair and the activation of sirtuins — the so-called longevity proteins whose activity is intimately linked to healthy ageing across species from yeast to humans. NAD+ levels decline progressively with age — by approximately 50% between the ages of 40 and 60 in most human tissue. When NAD+ falls, sirtuin activity falls with it. When sirtuin activity falls, the coordination between energy metabolism and longevity control that the NAD-sirtuin tango provides begins to falter.

The coupling of NAD+ breakdown and protein deacylation is a unique feature of the sirtuin family. The tight connection between NAD+ and sirtuins is regulated at several different levels, adding further complexity to their coordination in metabolic and ageing and longevity control. NAD+ availability decreases with age, reducing sirtuin activities and affecting the communication between the nucleus and mitochondria at a cellular level and also between the hypothalamus and adipose tissue at a systemic level.

Restoring NAD+ levels through precursor supplementation — NMN, NR or injectable NAD+ — is one of the most actively researched longevity interventions of the past decade. Understanding what the research actually shows — including the nuanced and sometimes contradictory human trial findings — is what this page provides.

What Is NAD+ and Why Does Its Decline Matter?

NAD+ is a dinucleotide coenzyme present in every cell in the body, where it functions as an electron carrier in the metabolic reactions that produce cellular energy through oxidative phosphorylation. Every time a cell burns glucose or fat for energy, NAD+ accepts electrons and is reduced to NADH, then reoxidised back to NAD+ by the electron transport chain — a cycle that underlies the fundamental chemistry of cellular energy production.

Beyond energy metabolism, NAD+ is a substrate for three families of enzymes that consume it in ways directly relevant to ageing biology. Sirtuins use NAD+ as a cofactor for their deacetylase activity — modifying histones and other proteins in ways that regulate gene expression, DNA repair, mitochondrial function and metabolic efficiency. PARPs use NAD+ for DNA damage repair — consuming significant amounts of NAD+ in response to genotoxic stress. And cADPR synthases use NAD+ for calcium signalling. The combined NAD+ consumption by these pathways means that cells are in a constant state of NAD+ production and consumption, and when the production side of that balance is impaired — as happens with age — the downstream effects on sirtuin activity, DNA repair and metabolic regulation are significant.

The age-related decline in NAD+ is not incidental. It reflects multiple converging biological changes — declining expression of the enzymes that synthesise NAD+ from precursors, increasing activity of the PARP enzymes that consume NAD+ in response to accumulated DNA damage, and changes in the NAD+ salvage pathway that normally recycles NAD+ metabolites back into the active coenzyme. The result is a progressive NAD+ deficit that compounds across decades.

NMN and NR — The Two Primary Precursors

NAD+ itself cannot be directly supplemented effectively — it does not cross cell membranes readily and has poor oral bioavailability. The practical approach to raising NAD+ levels is through precursor supplementation — compounds that are taken up by cells and converted to NAD+ through the salvage pathway.

NMN — Nicotinamide Mononucleotide

NMN is one step removed from NAD+ in the biosynthetic pathway — it is converted to NAD+ by the enzyme NMNAT in a single step. It has a specific transporter — Slc12a8 — that facilitates its uptake into cells, giving it a more direct route to intracellular NAD+ than some other precursors. NMN reliably raises blood NAD+ levels in human studies. It is the precursor most associated with David Sinclair’s longevity research at Harvard and the one that has attracted the most commercial attention and popular interest.

NR — Nicotinamide Riboside

NR is two steps removed from NAD+ — converted first to NMN and then to NAD+. It has a longer track record in human clinical trials than NMN and some of the most rigorous controlled bioavailability data available. NR also reliably raises blood NAD+ levels in human studies and has been commercially available longer than NMN, giving it a more mature safety dataset.

The Key Question

Both NMN and NR reliably raise circulating NAD+ levels — this is well established across multiple human studies. The more important and less clearly answered question is whether raising NAD+ levels in the blood translates into raising NAD+ levels in the specific tissues and cell types where NAD+ decline matters most for ageing biology — and whether that intracellular NAD+ elevation then produces the downstream sirtuin activation and metabolic improvements that the biological rationale predicts.

What Does the Research Actually Show?

The NAD+ precursor research base is more extensive than for virtually any other compound in the Longevity section — and the findings are more nuanced than either the enthusiastic popular narrative or the skeptical response to that narrative typically suggest.

NAD+ Elevation is Consistent

Across multiple human randomised controlled trials, both NMN and NR consistently and reliably raise circulating NAD+ levels — this finding is robustly established and not seriously disputed. MIB-626 — a pharmaceutical-grade extended-release NMN formulation — has demonstrated in Phase 1 studies that 1g twice daily is safe and effective in substantially raising circulating NAD+ levels in healthy adults.

The 2025 Meta-Analysis — An Important Honest Finding

A 2025 meta-analysis of 10 randomised controlled trials found no benefit for muscle mass, strength or physical function in older adults from NMN and NR supplementation. This is the most important piece of evidence to engage with honestly — and it reflects the gap between reliably raising NAD+ in the blood and producing meaningful functional outcomes in the specific tissue types and clinical endpoints that matter for ageing biology.

This finding does not mean NAD+ precursors are without benefit. It means that muscle mass, strength and physical function — the endpoints measured in that meta-analysis — are not reliably improved by NMN and NR at the doses studied over the timeframes studied. Other endpoints and other populations may tell a different story.

Where the Human Evidence is More Positive

A 2022 randomised controlled trial in postmenopausal women with prediabetes showed that NMN improved insulin sensitivity and skeletal muscle insulin signalling — a finding directly relevant to the metabolic mechanisms the biological rationale predicts. A 2023 trial in older adults showed NMN improved walking speed and gait speed — functional measures with genuine clinical relevance. A 2024 trial showed NR improved mitochondrial function markers in skeletal muscle — providing mechanistic confirmation of the predicted downstream pathway in human tissue. Research has shown improvements in aerobic capacity, muscle function and cognitive performance in specific populations.

The Blood-Brain Barrier Question

Whether NMN and NR cross the blood-brain barrier in humans remains unresolved. Although NR and NMN have been shown to cross the blood-brain barrier in animal models and attenuate Alzheimer’s pathology in preclinical models, no clinical trials have definitively determined whether NMN crosses the blood-brain barrier or engages the target mechanisms in the human brain. A 90-day randomised trial in mild Alzheimer’s dementia participants using MIB-626 is underway to address this specific question — one of the most clinically important outstanding questions in the NAD+ field.

Injectable NAD+

Injectable NAD+ — administered intravenously or intramuscularly — bypasses the absorption and conversion questions that complicate oral precursor supplementation. Intravenous NAD+ directly raises plasma NAD+ to significantly higher levels than oral precursors achieve and delivers the coenzyme in its active form rather than requiring cellular conversion. The clinical use of IV NAD+ has grown substantially in concierge medicine and longevity clinic settings, though the controlled trial evidence specifically for IV administration in longevity contexts is limited compared to the oral precursor database.

Who Is NAD+ Most Relevant For?

NAD+ precursor supplementation has the broadest relevant audience of any compound in the Longevity section — reflecting both the universality of NAD+ decline with age and the accessibility of oral NMN and NR supplementation relative to the injectable protocols required by most other longevity compounds.

It is most relevant for people in their 40s and beyond experiencing the energy, metabolic and recovery changes associated with progressive NAD+ decline — where the biological rationale for restoration is clearest and where the positive human trial signals for insulin sensitivity and mitochondrial function are most applicable.

It is specifically relevant as a foundational element of a comprehensive longevity protocol — the NAD+ and sirtuin axis connects to the telomere biology that Epithalon addresses, the mitochondrial function that SS-31 and MOTS-c address, the gene expression remodelling that GHK-Cu addresses and the cellular senescence that FOXO4-DRI addresses. Adequate NAD+ is a prerequisite for the optimal function of virtually every other mechanism in the longevity section.

It is most meaningful for anyone already maintaining the lifestyle foundations — exercise, sleep, stress management and nutrition — that are themselves the most powerful natural NAD+ supporters available. Exercise raises NAD+ through AMPK-mediated pathways. Caloric restriction raises NAD+ through reduced PARP consumption. These lifestyle factors and NAD+ precursor supplementation are synergistic rather than substitutable.

Dosage and Protocol

Oral NMN:

Dose: 500mg to 1,000mg once daily — the range used in most positive human trials
Timing: Morning administration with or without food — some evidence suggests taking NMN with a small amount of food improves absorption
Form: Standard NMN capsules or the extended-release MIB-626 formulation where available
Cycle: Oral NMN and NR are typically used continuously rather than cycled — the NAD+ restoration rationale supports ongoing supplementation

Oral NR:

Dose: 300mg to 1,000mg once or twice daily
Timing: Morning administration — NR’s effects on circadian NAD+ metabolism are most productive when aligned with the morning circadian window
Form: Standard NR capsules — Tru Niagen is the most clinically studied branded NR formulation

Injectable NAD+:

Dose: 250mg to 500mg per infusion administered intravenously over 1 to 4 hours, or 100mg to 250mg per intramuscular injection
Frequency: Weekly or twice monthly infusions for maintenance — more frequent initial loading protocols are used in some longevity clinic settings
Administration: IV infusions should be administered under appropriate supervision given the infusion reaction profile — flushing, chest tightness and nausea are common during rapid infusion and administration rate should be managed accordingly
Practical consideration: IV NAD+ is significantly more expensive and less accessible than oral precursors but produces dramatically higher plasma NAD+ elevations and bypasses the oral absorption and cellular conversion questions

A Note on Reconstitution

Injectable NAD+ comes as a powder requiring reconstitution with sterile water or normal saline for intravenous or intramuscular administration.

For intramuscular use — using a 500mg vial:

Add 2ml of sterile water:

Concentration = 250mg per ml
A 100mg dose = 0.4ml
A 250mg dose = 1ml

For intravenous infusion — the reconstituted NAD+ is typically further diluted in 250ml to 500ml of normal saline for administration over 1 to 4 hours.

Oral NMN and NR do not require reconstitution — they are taken directly as capsules or dissolved powder. This is the most practically accessible approach for most people and the form used in the majority of positive human clinical trials.

Storage

Reconstituted injectable NAD+ should be used promptly or refrigerated and used within 24 hours. Unreconstituted powder should be stored at room temperature away from light and moisture. Oral NMN and NR capsules should be stored as per manufacturer guidance — typically at room temperature away from light and humidity.

Supporting Supplements

The supplements that most coherently support NAD+ restoration and the sirtuin activation that follows are those that complement the NAD-sirtuin tango from different biological angles.

Resveratrol is the most directly complementary supplement alongside NMN or NR — activating SIRT1 through a mechanism that is synergistic with the NAD+ that NMN and NR restore. David Sinclair’s research programme at Harvard has consistently combined NMN with resveratrol on the basis of this synergy — both substances are required for the full sirtuin activation effect and neither alone produces what both together achieve.

Quercetin supports sirtuin activation through a related but distinct pathway and has the added senolytic dimension covered in the FOXO4-DRI page — making it a particularly relevant complement within a comprehensive longevity protocol.

Magnesium is essential for the ATP synthesis that NAD-dependent energy metabolism produces — directly relevant to the cellular energy production outcomes that NAD+ restoration is working to support.

CoQ10 supports the electron transport chain function that uses NADH — the reduced form of NAD+ — as its primary electron donor. Adequate CoQ10 ensures that the NADH produced from restored NAD+ metabolism is efficiently converted back to NAD+ through the electron transport chain.

Vitamin B3 forms — niacin specifically — can support the NAD+ salvage pathway through the Preiss-Handler pathway, complementing the NMN and NR routes to NAD+ restoration through an independent biosynthetic pathway.

Foods That Complement NAD+ Restoration

The nutritional approach that best supports NAD+ restoration provides natural NAD+ precursors through food, reduces the PARP-mediated NAD+ consumption that accumulated DNA damage drives and maintains the metabolic environment in which restored NAD+ levels translate into meaningful sirtuin activation.

NAD+ precursor-rich foods deserve specific emphasis alongside supplementation. Chicken, turkey, tuna, salmon, beef, mushrooms and green peas all contain meaningful amounts of niacin and related NAD+ precursor compounds — providing dietary NAD+ biosynthesis support that complements NMN and NR supplementation through natural food-based pathways.

Oily fish provides EPA and DHA alongside natural niacin content — combining the anti-inflammatory and NAD+ supportive dimensions in a single highly relevant food source.

Whole grains deliver niacin and the B vitamins that support the NAD+ biosynthesis pathways, alongside the fibre that supports the gut microbiome changes that NMN research has shown include increases in anti-inflammatory bacterial populations.

Broccoli and cruciferous vegetables

deliver NMN in small but meaningful natural quantities alongside sulforaphane that activates NRF2 — the master antioxidant transcription factor that reduces the oxidative DNA damage driving PARP-mediated NAD+ consumption.

Caloric moderation is worth specific mention alongside NAD+ supplementation. Caloric restriction and intermittent fasting both raise NAD+ levels through reduced PARP consumption and enhanced NAMPT expression — creating a dietary approach that complements supplementation from the production side of the NAD+ balance rather than simply adding more precursor to an environment that continues consuming NAD+ at an elevated rate.

Lifestyle Considerations

Exercise is the most powerful single lifestyle NAD+ supporter available — and its synergy with NAD+ precursor supplementation is one of the most practically significant interactions in the entire longevity section. High-intensity interval training and resistance training both raise NAD+ through AMPK-mediated NAMPT upregulation — the same enzyme that NMN depends on for its conversion to NAD+. The combination of exercise-driven NAD+ production and precursor-supplied substrate creates an environment where NAD+ restoration is more complete than either achieves independently.

Sleep quality directly influences NAD+ metabolism — the circadian clock regulates NAMPT expression and NAD+ biosynthesis in a rhythmic pattern that depends on consistent sleep timing. Disrupted circadian rhythms impair NAD+ biosynthesis regardless of precursor supplementation — making consistent sleep timing directly relevant to the NAD+ restoration that NMN and NR are working to achieve.

Avoiding alcohol is particularly important alongside NAD+ supplementation. Alcohol metabolism consumes NAD+ through aldehyde dehydrogenase reactions — directly depleting the NAD+ pool that supplementation is working to restore and creating a counterproductive cycle where alcohol consumption undermines what the protocol is trying to achieve.

Minimising DNA damage exposures — UV radiation, smoking, environmental toxins — reduces the PARP-mediated NAD+ consumption that accumulated DNA damage drives. The more DNA damage a cell is repairing, the more NAD+ is consumed by PARPs and the less is available for sirtuin activation and energy metabolism.

Compound Pairing

Resveratrol — covered in supplements — deserves mention in the pairing context as the compound most frequently and most evidence-supportedly combined with NMN, activating the SIRT1 pathway that restored NAD+ makes accessible.

MOTS-c complements NAD+ supplementation through the mitochondrial AMPK activation pathway — both approaches supporting mitochondrial energy production from different angles, with MOTS-c driving AMPK activation that NAMPT expression and NAD+ biosynthesis depend on.

SS-31 addresses the inner mitochondrial membrane structural integrity that the electron transport chain — which regenerates NAD+ from NADH — requires for efficient function. The combination of SS-31 restoring electron transport chain efficiency and NAD+ precursors providing the substrate creates a more complete mitochondrial energy production support approach.

Epithalon connects to NAD+ through the SIRT1 pathway — the sirtuin activation that NAD+ restoration enables includes SIRT1, which is involved in the epigenetic remodelling and telomere-associated gene regulation that Epithalon also engages through its epigenetic dimension.

GHK-Cu addresses the gene expression remodelling that sirtuin activation produces at the downstream level — the combination of NAD+ restoring the sirtuin activity and GHK-Cu supporting the gene expression environment in which sirtuin-mediated remodelling occurs creates a more comprehensive epigenetic longevity approach.

Realistic Expectations

NAD+ precursor supplementation is both the most extensively studied and the most honestly complicated longevity intervention in this section — and engaging with it productively requires holding both the genuine strength of the biological rationale and the genuine nuance of the human evidence simultaneously.

NMN and NR reliably raise circulating NAD+ levels — this is established. Whether that NAD+ elevation reaches the specific intracellular compartments and tissue types where NAD+ decline matters most for longevity biology is less clearly established. Whether the raised NAD+ then activates sirtuins at meaningful levels in those tissues is less clearly established still. And whether that sirtuin activation produces the specific functional outcomes measured in clinical trials is where the 2025 meta-analysis found the evidence wanting for muscle mass and physical function.

What the human evidence does support positively includes improvements in insulin sensitivity in specific populations, mitochondrial function markers in skeletal muscle, gait speed in older adults and the consistent and reliable elevation of NAD+ that is the prerequisite for all downstream effects. These are real and meaningful findings — not as dramatic as the most enthusiastic popular narrative suggests, but not as empty as the most sceptical response implies.

The most meaningful application of NAD+ supplementation is as a foundational element of a comprehensive longevity protocol rather than as a standalone intervention — providing the cellular energy currency and sirtuin substrate that virtually every other mechanism in this section depends on to function optimally. Used consistently alongside the exercise that independently raises NAD+, the sleep that supports circadian NAD+ biosynthesis, the nutrition that provides natural precursors and reduces PARP consumption, and the complementary longevity compounds that address the specific hallmarks of ageing that restored NAD+ helps to engage — NAD+ supplementation occupies a genuinely important and well-reasoned place in the most comprehensive longevity approaches available in 2026.